EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Antibody-binding sites on truncated forms of varicella-zoster virus gpI(gE) glycoprotein






Vaccine 12(14): 1265-1269

Antibody-binding sites on truncated forms of varicella-zoster virus gpI(gE) glycoprotein

Varicella-zoster virus (VZV)-seropositive human sera were shown to be reactive with the truncated VZV gpI(gE) candidate subunit vaccine (TgpI-511). To identify the location of antibody-binding sites (epitopes) on TgpI-511, three truncated forms of TgpI-511 glycoprotein (TgpI-124, TgpI-160, TgpI-316) DNA encoding the N-terminal region of this glycoprotein with amino acid residues of 124, 160 and 360, respectively, were inserted into the vaccinia virus genome. Infection of cells with recombinant vaccinia viruses resulted in the secretion of all three truncated gpI(gE) as well as TgpI-511 from the infected cells. Immunoprecipitation of these truncated glycoproteins with VZV-seropositive human sera and gpI(gE)-specific monoclonal antibodies identified the location of four new antibody-binding sites on the VZV TgpI-511 glycoprotein. In addition, tunicamycin treatment and O-glycanase digestion revealed the presence of both N-linked and O-linked oligosaccharides on TgpI-511. These results revealed the location of new epitopes on VZV TgpI-511 and demonstrated that the epitopes on TgpI-511 were recognized by human sera from VZV-seropositive individuals.

Accession: 009770392

PMID: 7531921

DOI: 10.1016/s0264-410x(94)80030-4

Download PDF Full Text: Antibody-binding sites on truncated forms of varicella-zoster virus gpI(gE) glycoprotein



Related references

In vivo expression of a DNA vaccine encoding truncated and full length forms of Varicella-Zoster Virus glycoprotein E fused to enhanced green fluorescent protein. Immunology 98(suppl 1): 129, 1999

Induction of neutralizing antibody against varicella zoster virus by varicella zoster virus by gp 3 and cross reactivity between varicella zoster virus gp 3 and herpes simplex viruses gb. Virology 149(1): 74-82, 1986

Immunization with a DNA vaccine expressing a truncated form of varicella zoster virus glycoprotein E. Vaccine 20(9-10): 1308-1315, 31 January, 2002

Construction of a truncated varicella zoster glycoprotein iv gene in a vaccinia virus expression vector. Clinical Research 39(1): 59A, 1991

Immunization with a DNA vaccine expressing a truncated form of Varicella-zoster virus glycoprotein E produced by inverse PCR mutagenesis. Immunology 98(suppl 1): 129, 1999

Neutralization epitope of varicella zoster virus on native viral glycoprotein gp 118 varicella zoster virus glycoprotein gp iii. Virology 149(2): 230-241, 1986

Inhibition of varicella-zoster virus (VZV) glycoprotein expression by a human monoclonal antibody against VZV glycoprotein III. Journal of Infectious Diseases 168(5): 1256-1259, 1993

Purification of individual varicella zoster virus glycoproteins gp i gp ii and gp iii and their use in elisa for detection of varicella zoster virus glycoprotein specific antibodies. Journal of Virological Methods 14(2): 177-188, 1986

Immunogenicity in mice of varicella-zoster virus glycoprotein I expressed by a vaccinia virus-varicella-zoster virus recombinant. Journal of General Virology 72: 1445-1449, 1991

A chimeric antibody to varicella-zoster virus glycoprotein e. Hybridoma 24(1): 50-54, 2005